Document is current
Any future updates will be listed below
-
Authors
Oliveira, Liliana https://orcid.org/0000-0001-5222-7600
Silva, M. Carolina https://orcid.org/0009-0008-1516-5250
Gomes, Ana P.
Santos, Rita F.
Cardoso, Marcos S. https://orcid.org/0000-0003-0150-7359
Nóvoa, Ana https://orcid.org/0000-0002-5668-5630
Luche, Hervé https://orcid.org/0000-0003-4309-8338
Cavadas, Bruno
Amorim, Irina https://orcid.org/0000-0002-2305-1631
Gärtner, Fátima
Malissen, Bernard https://orcid.org/0000-0003-1340-9342
Mallo, Moisés https://orcid.org/0000-0002-9744-0912
Carmo, Alexandre M. https://orcid.org/0000-0002-2508-9799
- License Information
-
More Information
Article History
Received: 17 February 2023
Accepted: 29 April 2024
First Online: 15 May 2024
Competing interests
: L.O. and A.M.C. are inventors on the patent application “Recombinant Human CD5L protein, active fragments or peptides derived thereof and pharmaceutical composition comprising the recombinant human CD5L protein, active fragments or peptides derived thereof for the treatment of acute infectious diseases, inflammatory diseases and sepsis”, applicants, IBMC (Instituto de Biologia Molecular e Celular) and INVIGATE GmbH, WO2023/146425, published in 03.08.2023. The remaining authors declare no competing interests.
